Fate Therapeutics
FATE
188 hedge funds and large institutions have $520M invested in Fate Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 60 increasing their positions, 58 reducing their positions, and 24 closing their positions.
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
4% more funds holding
Funds holding: 181 → 188 (+7)
3% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 58
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.66% less ownership
Funds ownership: 114.6% → 110.94% (-3.7%)
19% less capital invested
Capital invested by funds: $642M → $520M (-$122M)
55% less call options, than puts
Call options by funds: $173K | Put options by funds: $382K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$9.02M |
| 2 |
JP Morgan Chase
New York
|
+$5.54M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.47M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.04M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.9M |
| 2 |
AG
Artal Group
Luxembourg
|
-$14.8M |
| 3 |
Millennium Management
New York
|
-$6.11M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5.15M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$3.68M |
FATE Hedge Fund Activity: Q2 2023 in Review
188 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2023, worth a combined $520M — down 19% from $642M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new FATE positions and 24 closed out — a net gain of 8 holders — while 60 added to existing stakes and 58 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $9.02M. The largest seller was State Street, cutting an estimated $24.9M.
- 188 institutional investors held Fate Therapeutics (FATE) as of Q2 2023, up from 181 in Q1 2023.
- Funds reported $520M of Fate Therapeutics stock for Q2 2023, down 19% quarter-over-quarter.
- 32 funds opened new Fate Therapeutics positions in Q2 2023 and 24 closed out, a net change of +8 holders.
- The largest Fate Therapeutics buyer in Q2 2023 was D.E. Shaw & Co, an estimated $9.02M added.
- The largest Fate Therapeutics seller in Q2 2023 was State Street, an estimated $24.9M sold.
Based on aggregated 13F filings for Q2 2023.